The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place.
Government is expanding prescription coverage for long-acting muscarinic antagonist (LAMAs) inhalers, used in the treatment of Chronic Obstructive Pulmonary Disease. The change to open listing on the NL Prescription Drug Program reduces the administrative burden of prescribers by eliminating the special authorization process that had been in place. This will ensure NLPDP beneficiaries have timely access to these inhalers for the treatment of their COPD.
Port Saunders RCMP looks for missing man, 55-year-old Sheldon Wells
New gravel quarry in Bay St. George gets government approval
RCMP offers safety tips as the big game hunting season in many parts of NL has opened
Humber Arm South man facing charges after stealing a vehicle and fleeing from police
